Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates

PHASE3RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 20, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
BPD
Interventions
BIOLOGICAL

autologous cord blood mononuclear cells

preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth

BIOLOGICAL

normal saline

preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth

Trial Locations (2)

511442

RECRUITING

Jie Yang, Guangzhou

Unknown

RECRUITING

Ren Xuejun, Dongguan

All Listed Sponsors
collaborator

Foshan Fuxing Chancheng Central Hospital

UNKNOWN

collaborator

Foshan Women's and Children's Hospital

OTHER

collaborator

Hexian Memorial Affiliated Hospital of Southern Medical University

UNKNOWN

collaborator

Heyuan Women and Children Hospital

UNKNOWN

collaborator

Dongguan Women and Children Hospital

UNKNOWN

collaborator

Guangzhou Huadu Women and Children Hospital

UNKNOWN

collaborator

Shunde Women and Children Hospital

UNKNOWN

collaborator

Guangdong Cord Blood Bank

INDUSTRY

collaborator

Huangdu Distric Women and Children Hospital

UNKNOWN

collaborator

Longgang Distric Women and Children Hospital,Shenzhen

UNKNOWN

collaborator

BoAi Hospital of Zhongshan

OTHER

collaborator

Huizhou first Women and Children Hospital

UNKNOWN

collaborator

Huizhou second Women and Children Hospital

UNKNOWN

lead

Guangdong Women and Children Hospital

OTHER

NCT04440670 - Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates | Biotech Hunter | Biotech Hunter